Fisher to sell diaDexus' PLAC in US:
This article was originally published in Clinica
Diagnostics firm diaDexus is set to make its automated PLAC blood test available in the US through Fisher HealthCare. Fisher will sell the test, which was cleared for use with Hitachi, Hitachi Roche P-Modular and Olympus chemistry analysers by the FDA in February 2008 (see Clinica No 1296, p 26), to US hospital clinical laboratories. According to South San Francisco, California-based diaDexus, the product is the only FDA-cleared blood test to asses risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. Financial details of the deal were not disclosed.
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”